APO Research
Talk to an analyst

APO RESEARCH · REPORT

Inactivated Poliovirus Vaccine

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Inactivated Poliovirus Vaccine Market Outlook and Growth Opportunities 2026

22 December 2025190 pages

Choose your research edition.

Industry ResearchInactivated Poliovirus Vaccine Industry Research Report 2026107 pages · $2,950 USDIndustry Growth & TrendsGlobal Inactivated Poliovirus Vaccine Industry Growth and Trends Forecast to 203271 pages · $3,450 USDMarket StructureGlobal Inactivated Poliovirus Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032170 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Inactivated Poliovirus Vaccine Market Outlook and Growth Opportunities 2026190 pages · $4,250 USDMarket Analysis & ForecastGlobal Inactivated Poliovirus Vaccine Market Analysis and Forecast 2026-2032195 pages · $4,950 USD

Market perspective

The global Inactivated Poliovirus Vaccine market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Inactivated Poliovirus Vaccine is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Inactivated Poliovirus Vaccine market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Inactivated Poliovirus Vaccine market include Sanofi, GSK, Serum Institute (Bilthoven Biologicals) and IMBCA, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Inactivated Poliovirus Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Inactivated Poliovirus Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Inactivated Poliovirus Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Inactivated Poliovirus Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Inactivated Poliovirus Vaccine Segment by Company

Sanofi

GSK

Serum Institute (Bilthoven Biologicals)

IMBCA

Inactivated Poliovirus Vaccine Segment by Type

Human Diploid Cell

Monkey Kidney Cell

Inactivated Poliovirus Vaccine Segment by Application

Public

Private

Inactivated Poliovirus Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Inactivated Poliovirus Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Inactivated Poliovirus Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Inactivated Poliovirus Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Inactivated Poliovirus Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Inactivated Poliovirus Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Inactivated Poliovirus Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Inactivated Poliovirus Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Inactivated Poliovirus Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Inactivated Poliovirus Vaccine industry.

Chapter 3: Detailed analysis of Inactivated Poliovirus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Inactivated Poliovirus Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Inactivated Poliovirus Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Inactivated Poliovirus Vaccine Industry Trends Table 2. Inactivated Poliovirus Vaccine Industry Drivers Table 3. Inactivated Poliovirus Vaccine Industry Opportunities and Challenges Table 4. Inactivated Poliovirus Vaccine Industry Restraints Table 5. Global Inactivated Poliovirus Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Inactivated Poliovirus Vaccine Revenue Share by Company (2021-2026) Table 7. Global Inactivated Poliovirus Vaccine Sales Volume by Company (k units) & (2021-2026) Table 8. Global Inactivated Poliovirus Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Inactivated Poliovirus Vaccine Average Price (US$/unit) of Company (2021-2026) Table 10. Global Inactivated Poliovirus Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Inactivated Poliovirus Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Inactivated Poliovirus Vaccine Company, Product Type & Application Table 13. Global Inactivated Poliovirus Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Inactivated Poliovirus Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Human Diploid Cell Table 18. Significant Companies of Monkey Kidney Cell Table 19. Global Inactivated Poliovirus Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (k units) Table 20. Global Inactivated Poliovirus Vaccine Sales Volume by Type (2021-2026) & (k units) Table 21. Global Inactivated Poliovirus Vaccine Sales Volume by Type (2027-2032) & (k units) Table 22. Global Inactivated Poliovirus Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Inactivated Poliovirus Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Inactivated Poliovirus Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Inactivated Poliovirus Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Inactivated Poliovirus Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Inactivated Poliovirus Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Inactivated Poliovirus Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Public Table 30. Significant Companies of Private Table 31. Global Inactivated Poliovirus Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (k units) Table 32. Global Inactivated Poliovirus Vaccine Sales Volume by Application (2021-2026) & (k units) Table 33. Global Inactivated Poliovirus Vaccine Sales Volume by Application (2027-2032) & (k units) Table 34. Global Inactivated Poliovirus Vaccine Sales Volume Share by Application (2021-2026) Table 35. Global Inactivated Poliovirus Vaccine Sales Volume Share by Application (2027-2032) Table 36. Global Inactivated Poliovirus Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Inactivated Poliovirus Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 38. Global Inactivated Poliovirus Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 39. Global Inactivated Poliovirus Vaccine Sales Value Share by Application (2021-2026) Table 40. Global Inactivated Poliovirus Vaccine Sales Value Share by Application (2027-2032) Table 41. Global Inactivated Poliovirus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Table 42. Global Inactivated Poliovirus Vaccine Sales by Region (2021-2026) & (k units) Table 43. Global Inactivated Poliovirus Vaccine Sales Market Share by Region (2021-2026) Table 44. Global Inactivated Poliovirus Vaccine Sales by Region (2027-2032) & (k units) Table 45. Global Inactivated Poliovirus Vaccine Sales Market Share by Region (2027-2032) Table 46. Global Inactivated Poliovirus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 47. Global Inactivated Poliovirus Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 48. Global Inactivated Poliovirus Vaccine Sales Value Share by Region (2021-2026) Table 49. Global Inactivated Poliovirus Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 50. Global Inactivated Poliovirus Vaccine Sales Value Share by Region (2027-2032) Table 51. Global Inactivated Poliovirus Vaccine Market Average Price (US$/unit) by Region (2021-2026) Table 52. Global Inactivated Poliovirus Vaccine Market Average Price (US$/unit) by Region (2027-2032) Table 53. Global Inactivated Poliovirus Vaccine Sales by Country: 2021 VS 2025 VS 2032 (k units) Table 54. Global Inactivated Poliovirus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 55. Global Inactivated Poliovirus Vaccine Sales by Country (2021-2026) & (k units) Table 56. Global Inactivated Poliovirus Vaccine Sales Market Share by Country (2021-2026) Table 57. Global Inactivated Poliovirus Vaccine Sales by Country (2027-2032) & (k units) Table 58. Global Inactivated Poliovirus Vaccine Sales Market Share by Country (2027-2032) Table 59. Global Inactivated Poliovirus Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 60. Global Inactivated Poliovirus Vaccine Sales Value Market Share by Country (2021-2026) Table 61. Global Inactivated Poliovirus Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 62. Global Inactivated Poliovirus Vaccine Sales Value Market Share by Country (2027-2032) Table 63. Sanofi Company Information Table 64. Sanofi Business Overview Table 65. Sanofi Inactivated Poliovirus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 66. Sanofi Inactivated Poliovirus Vaccine Product Portfolio Table 67. Sanofi Recent Development Table 68. GSK Company Information Table 69. GSK Business Overview Table 70. GSK Inactivated Poliovirus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 71. GSK Inactivated Poliovirus Vaccine Product Portfolio Table 72. GSK Recent Development Table 73. Serum Institute (Bilthoven Biologicals) Company Information Table 74. Serum Institute (Bilthoven Biologicals) Business Overview Table 75. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 76. Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Product Portfolio Table 77. Serum Institute (Bilthoven Biologicals) Recent Development Table 78. IMBCA Company Information Table 79. IMBCA Business Overview Table 80. IMBCA Inactivated Poliovirus Vaccine Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 81. IMBCA Inactivated Poliovirus Vaccine Product Portfolio Table 82. IMBCA Recent Development Table 83. Key Raw Materials Table 84. Raw Materials Key Suppliers Table 85. Inactivated Poliovirus Vaccine Distributors List Table 86. Inactivated Poliovirus Vaccine Customers List Table 87. Research Programs/Design for This Report Table 88. Authors List of This Report Table 89. Secondary Sources Table 90. Primary Sources List of Figures Figure 1. Inactivated Poliovirus Vaccine Product Image Figure 2. Global Inactivated Poliovirus Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Inactivated Poliovirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Inactivated Poliovirus Vaccine Sales (2021-2032) & (k units) Figure 5. Global Inactivated Poliovirus Vaccine Sales Average Price (US$/unit) & (2021-2032) Figure 6. Global Inactivated Poliovirus Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Human Diploid Cell Image Figure 10. Monkey Kidney Cell Image Figure 11. Global Inactivated Poliovirus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (k units) Figure 12. Global Inactivated Poliovirus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Inactivated Poliovirus Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Inactivated Poliovirus Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Inactivated Poliovirus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Inactivated Poliovirus Vaccine Sales Value Share by Type (2021-2032) Figure 17. Public Image Figure 18. Private Image Figure 19. Global Inactivated Poliovirus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (k units) Figure 20. Global Inactivated Poliovirus Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 21. Global Inactivated Poliovirus Vaccine Sales Volume Share by Application (2021-2032) Figure 22. Global Inactivated Poliovirus Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 23. Global Inactivated Poliovirus Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 24. Global Inactivated Poliovirus Vaccine Sales Value Share by Application (2021-2032) Figure 25. Global Inactivated Poliovirus Vaccine Sales by Region: 2021 VS 2025 VS 2032 (k units) Figure 26. Global Inactivated Poliovirus Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 27. Global Inactivated Poliovirus Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 28. Global Inactivated Poliovirus Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 29. North America Inactivated Poliovirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 30. North America Inactivated Poliovirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 31. Europe Inactivated Poliovirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 32. Europe Inactivated Poliovirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Asia-Pacific Inactivated Poliovirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 34. Asia-Pacific Inactivated Poliovirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 35. South America Inactivated Poliovirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 36. South America Inactivated Poliovirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 37. Middle East & Africa Inactivated Poliovirus Vaccine Sales Value (2021-2032) & (US$ Million) Figure 38. Middle East & Africa Inactivated Poliovirus Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 39. USA Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. USA Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. USA Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. Canada Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. Canada Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. Canada Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. Mexico Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. Mexico Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. Mexico Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Germany Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Germany Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Germany Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. France Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. France Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. France Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. U.K. Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. U.K. Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. U.K. Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Italy Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Italy Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Italy Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Spain Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Spain Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Spain Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. Russia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. Russia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. Russia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Netherlands Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Netherlands Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Netherlands Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. Nordic Countries Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. Nordic Countries Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. Nordic Countries Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. China Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. China Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. China Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Japan Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Japan Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Japan Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. South Korea Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. South Korea Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. South Korea Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. India Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. India Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. India Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Australia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Australia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Australia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Southeast Asia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Southeast Asia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Southeast Asia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Brazil Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Brazil Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Brazil Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Argentina Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Argentina Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Argentina Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Chile Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Chile Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Chile Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Colombia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Colombia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Colombia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. Peru Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. Peru Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. Peru Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Saudi Arabia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Saudi Arabia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Israel Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Israel Arabia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Israel Arabia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. UAE Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. UAE Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. UAE Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Turkey Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 115. Turkey Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 116. Turkey Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 117. Iran Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 118. Iran Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 119. Iran Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 120. Egypt Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 121. Egypt Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 122. Egypt Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 123. Inactivated Poliovirus Vaccine Value Chain Figure 124. Manufacturing Cost Structure Figure 125. Inactivated Poliovirus Vaccine Sales Mode & Process Figure 126. Direct Comparison with Distribution Share Figure 127. Distributors Profiles Figure 128. Years Considered Figure 129. Research Process Figure 130. Key Executives Interviewed

Scope & coverage.

Types
  • Human Diploid Cell
  • Monkey Kidney Cell
Applications
  • Public
  • Private
Companies covered
  • Sanofi
  • GSK
  • Serum Institute (Bilthoven Biologicals)
  • IMBCA

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Inactivated Poliovirus Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Inactivated Poliovirus Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Inactivated Poliovirus Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Inactivated Poliovirus Vaccine Market Dynamics
  1. 2.1 Inactivated Poliovirus Vaccine Industry Trends
  2. 2.2 Inactivated Poliovirus Vaccine Industry Drivers
  3. 2.3 Inactivated Poliovirus Vaccine Industry Opportunities and Challenges
  4. 2.4 Inactivated Poliovirus Vaccine Industry Restraints
3 Inactivated Poliovirus Vaccine Market by Company
  1. 3.1 Global Inactivated Poliovirus Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Inactivated Poliovirus Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Inactivated Poliovirus Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Inactivated Poliovirus Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Inactivated Poliovirus Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Inactivated Poliovirus Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Inactivated Poliovirus Vaccine Company Product Type and Application
  8. 3.8 Global Inactivated Poliovirus Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Inactivated Poliovirus Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Inactivated Poliovirus Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Inactivated Poliovirus Vaccine Market by Type
  1. 4.1 Inactivated Poliovirus Vaccine Type Introduction
  2. 4.1.1 Human Diploid Cell
  3. 4.1.2 Monkey Kidney Cell
  4. 4.2 Global Inactivated Poliovirus Vaccine Sales Volume by Type
  5. 4.2.1 Global Inactivated Poliovirus Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Inactivated Poliovirus Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Inactivated Poliovirus Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Inactivated Poliovirus Vaccine Sales Value by Type
  9. 4.3.1 Global Inactivated Poliovirus Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Inactivated Poliovirus Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Inactivated Poliovirus Vaccine Sales Value Share by Type (2021-2032)
5 Inactivated Poliovirus Vaccine Market by Application
  1. 5.1 Inactivated Poliovirus Vaccine Application Introduction
  2. 5.1.1 Public
  3. 5.1.2 Private
  4. 5.2 Global Inactivated Poliovirus Vaccine Sales Volume by Application
  5. 5.2.1 Global Inactivated Poliovirus Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global Inactivated Poliovirus Vaccine Sales Volume by Application (2021-2032)
  7. 5.2.3 Global Inactivated Poliovirus Vaccine Sales Volume Share by Application (2021-2032)
  8. 5.3 Global Inactivated Poliovirus Vaccine Sales Value by Application
  9. 5.3.1 Global Inactivated Poliovirus Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  10. 5.3.2 Global Inactivated Poliovirus Vaccine Sales Value by Application (2021-2032)
  11. 5.3.3 Global Inactivated Poliovirus Vaccine Sales Value Share by Application (2021-2032)
6 Inactivated Poliovirus Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Inactivated Poliovirus Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Inactivated Poliovirus Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Inactivated Poliovirus Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Inactivated Poliovirus Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Inactivated Poliovirus Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Inactivated Poliovirus Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Inactivated Poliovirus Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Inactivated Poliovirus Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Inactivated Poliovirus Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Inactivated Poliovirus Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Inactivated Poliovirus Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Inactivated Poliovirus Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Inactivated Poliovirus Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Inactivated Poliovirus Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Inactivated Poliovirus Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Inactivated Poliovirus Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Inactivated Poliovirus Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Inactivated Poliovirus Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Inactivated Poliovirus Vaccine Sales Value Share by Country, 2025 VS 2032
7 Inactivated Poliovirus Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Inactivated Poliovirus Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Inactivated Poliovirus Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Inactivated Poliovirus Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Inactivated Poliovirus Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Inactivated Poliovirus Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Inactivated Poliovirus Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Inactivated Poliovirus Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Inactivated Poliovirus Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Inactivated Poliovirus Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Inactivated Poliovirus Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Inactivated Poliovirus Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Sanofi
  2. 8.1.1 Sanofi Company Information
  3. 8.1.2 Sanofi Business Overview
  4. 8.1.3 Sanofi Inactivated Poliovirus Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Sanofi Inactivated Poliovirus Vaccine Product Portfolio
  6. 8.1.5 Sanofi Recent Developments
  7. 8.2 GSK
  8. 8.2.1 GSK Company Information
  9. 8.2.2 GSK Business Overview
  10. 8.2.3 GSK Inactivated Poliovirus Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 GSK Inactivated Poliovirus Vaccine Product Portfolio
  12. 8.2.5 GSK Recent Developments
  13. 8.3 Serum Institute (Bilthoven Biologicals)
  14. 8.3.1 Serum Institute (Bilthoven Biologicals) Company Information
  15. 8.3.2 Serum Institute (Bilthoven Biologicals) Business Overview
  16. 8.3.3 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Serum Institute (Bilthoven Biologicals) Inactivated Poliovirus Vaccine Product Portfolio
  18. 8.3.5 Serum Institute (Bilthoven Biologicals) Recent Developments
  19. 8.4 IMBCA
  20. 8.4.1 IMBCA Company Information
  21. 8.4.2 IMBCA Business Overview
  22. 8.4.3 IMBCA Inactivated Poliovirus Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 IMBCA Inactivated Poliovirus Vaccine Product Portfolio
  24. 8.4.5 IMBCA Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Inactivated Poliovirus Vaccine Value Chain Analysis
  2. 9.1.1 Inactivated Poliovirus Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Inactivated Poliovirus Vaccine Sales Mode & Process
  6. 9.2 Inactivated Poliovirus Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Inactivated Poliovirus Vaccine Distributors
  9. 9.2.3 Inactivated Poliovirus Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst